Qiu Z, Chen L, Lin Q, et al. Perioperative outcomes and mid-term effects in performing video-assisted thoracoscopic extended thymectomy for myasthenia gravis: subxiphoid versus right thoracic ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States solely dedicated to the myasthenia gravis (MG) community, announced the ...

Concluding a recent interview with Jonathan Strober, MD, an investigator on the phase 2/3 Vibrance-MG study (NCT05265273) exploring pediatric use of nipocalimab for generalized myasthenia gravis ...

SOURCE Myasthenia Gravis Foundation of America, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging. Jonathan Strober, MD ...

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

Myasthenia gravis is a rare, chronic autoimmune disorder that causes serious muscle weakness. More for You. Frustrated Democrats try new response to Trump barrage: Flood the zone right back.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

Cartesian Therapeutics enrolls first participant in Phase 3 trial of Descartes-08 for myasthenia gravis treatment. Quiver AI Summary. Cartesian Therapeutics, Inc. has announced the enrollment of ...

According to the data, after 24 weeks of treatment, 98.1% of patients in the Telitacicept group demonstrated a ≥ 3-point improvement in Myasthenia Gravis Activities of Daily Living ("MG-ADL ...

Myasthenia gravis with hyperthyroidism and exophthalmic goiter has been reported. Eaton is quoted by McEachern and Parnell 2 as stating that 6 per cent of myasthenic patients studied at the Mayo ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...